OPTImal PHARMacological therapy for patients with heart failure: Rationale and design of the OPTIPHARM‐HF registry
Riccardo M. Inciardi,Muthiah Vaduganathan,Carlo M. Lombardi,Cristina Gussago,Piergiuseppe Agostoni,Pietro Ameri,Nadia Aspromonte,Leonardo Calò,Matteo Cameli,Erberto Carluccio,Stefano Carugo,Manlio Cipriani,Raffaele De Caterina,Gaetano M. De Ferrari,Michele Emdin,Alessandra Fornaro,Marco Guazzi,Massimo Iacoviello,Massimo Imazio,Maria Teresa La Rovere,Sergio Leonardi,Marta Maccallini,Daniele Masarone,Luigi Moschini,Alberto Palazzuoli,Giuseppe Patti,Roberto F.E. Pedretti,Pasquale Perrone Filardi,Massimo F. Piepoli,Luciano Potena,Andrea Salzano,Angela Sciacqua,Michele Senni,Gianfranco Sinagra,Claudia Specchia,Stefano Taddei,Dario Vizza,Gianluigi Savarese,Giuseppe Rosano,Maurizio Volterrani,Marco Metra,on behalf of the OPTIPHARM‐HF investigators
DOI: https://doi.org/10.1002/ejhf.3260
2024-06-25
European Journal of Heart Failure
Abstract:Aims Patients with heart failure (HF) remain often undertreated for multiple reasons, including treatment inertia, contraindications, and intolerance. The OPTIimal PHARMacological therapy for patients with Heart Failure (OPTIPHARM‐HF) registry is designed to evaluate the prevalence of evidence‐based medical treatment prescription and titration, as well as the causes of its underuse, in a broad real‐world population of consecutive patients with HF across the whole ejection fraction spectrum and among different clinical phenotypes. Methods The OPTIPHARM‐HF registry (NCT06192524) is a prospective, multicenter, observational, national study of adult patients with symptomatic HF, as defined by current international guidelines, regardless of ejection fraction. Both outpatients and inpatients with chronic and acute decompensated HF will be recruited. The study will enroll up to 2500 patients with chronic HF at approximately 35 Italian HF centres. Patients will be followed for a maximum duration of 24 months. The primary objective of the OPTIPHARM‐HF registry is to assess prescription and adherence to evidence‐based guideline‐directed medical therapy (GDMT) in patients with HF. The primary outcome is to describe the prevalence of GDMT use according to target guideline recommendation. Secondary objectives include implementation of comorbidity treatment, evaluation of sequence of treatment introduction and up‐titration, description of GDMT implementation in the specific HF population, main causes of GDMT underuse, and assessment of cumulative rate of cardiovascular events. Conclusion The OPTIPHARM‐HF registry will provide important implications for improving patient care and adoption of recommended medical therapy into clinical practice among HF patients.
cardiac & cardiovascular systems